Åke Ohlsson

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

A Follow-Up Study of Cleft Lip and Palate Patients Treated with Orthodontics, Secondary Bone Grafting, and Prosthetic Rehabilitation

Bengt Johanson, Åke Ohlsson, Hans Friede et al. · Scandinavian Journal of Plastic and Reconstructive Surgery · 1974 · 86 citations

Cleft Lip, Bone Grafting, Medicine +14

Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer

Åke Ohlsson, Tom Bennett, Rolf Nordlander et al. · Journal of Cardiac Failure · 1995 · 51 citations

Pulmonary Arterial Hypertension, Pulmonary Circulation, Cardiac Mechanic +7

Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: The Swedish Early Decision (SWEDES) reperfusion trial

Leif Svensson, Mikael Aasa, Mikael Dellborg et al. · American Heart Journal · 2006 · 48 citations

Thrombosis, Percutaneous Coronary Intervention, Reperfusion Trial +10